Relationship between serum interleukin-17 level and inflammatory bowel disease

Area of Science:

• Immunology
• Gastroenterology

Background:

• Inflammatory bowel disease (IBD), encompassing Crohn's disease (CD) and ulcerative colitis (UC), is a chronic condition with complex pathogenesis.
• Key cytokines like interleukin-17A (IL-17A), IL-10, and interferon-gamma (IFN-γ) are implicated in IBD.

Purpose of the Study:

• To investigate the role of IL-17A, IL-10, and IFN-γ in the pathogenesis of IBD.
• To analyze the expression of these cytokines in serum and colonic mucosa of IBD patients.

Main Methods:

• Serum samples from 28 CD patients, 74 UC patients, and 36 healthy controls were analyzed.
• Enzyme-linked immunosorbent assay (ELISA) was used to quantify IL-17A, IL-10, and IFN-γ levels.
• Immunohistochemical assays detected local IL-17A expression in colonic mucosa.

Main Results:

• Serum IL-17A levels were significantly higher in both CD and UC groups compared to controls (p<0.05).
• IL-17A was locally expressed in the colonic mucosa of IBD patients but not in controls.
• IL-10 levels were highest in the UC group (p<0.05), while IFN-γ levels showed no significant differences across groups.

Conclusions:

• IL-17A is significantly elevated in both serum and colonic tissue of IBD patients.
• The high expression of IL-17A suggests its involvement in IBD pathogenesis and potential role in disease relapse.
• Targeting IL-17A presents a promising therapeutic avenue for managing IBD.